Business
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
Dosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are never-smokers and
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nDosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are never-smokers and who make up 15-20% of all lung cancer cases.\n\n\n\nSubmission of the IND application for LP-184 to the US Food and Drug Administration (FDA) is anticipated this week; a first-in-human Phase 1 clinical trial for LP-184, in genomically defined solid tumors, is targeted to launch in mid-2023.\n\n\n\nCompletion of IND-enabling studies for LP-284 is anticipated for mid-2023; a first-in-human Phase 1 clinical trial for LP-284, in multiple non-Hodgkin’s lymphomas, is targeted to launch in the second half of 2023.\n\n\n\nReceived a notice of allowance from the United States Patent and Trademark Office (USPTO) for a composition of matter patent for LP-284.\n\n\n\nDeveloped industry-leading AI algorithms to predict the blood-brain-barrier permeability of any compound; the algorithms have been fully incorporated into Lantern’s AI platform RADR® increasing its functionality.\n\n\n\nEstablished an additional RADR® collaboration with TTC Oncology to help advance their Phase 2 ready drug candidate TTC-352 in ER+ breast cancer.\n\n\n\n$51.5 million in cash, cash equivalents, and marketable securities as of March 31, 2023.\n\n\n\nLantern has a cash runway into 2025.\n\n\n\nConference call scheduled for 4:30 p.m. ET / 1:30 p.m. PT today.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2023.\n\n\n“This quarter we continued to execute our mission of transforming the oncology drug discovery and development process using our industry-leading AI platform RADR®. We are deploying AI at a massive scale - think millions of simultaneous instances of competing and synergistic algorithms - to determine drug and cancer correlations that would be far too complex and time-consuming for any team of humans to fully analyze, let alone replicate. AI is enabling us to understand and predict drug-cancer interactions, create new drug programs, and discover cancer biolo...